Skip to main content
. 2020 Apr 20;20:336. doi: 10.1186/s12885-020-06716-5

Fig. 1.

Fig. 1

Study design. The TENERGY trial consists of two parts. After completion of definitive chemoradiotherapy, patients with primary locally advanced esophageal squamous cell carcinoma (ESCC) will be enrolled into the primary locally advanced ESCC part (N = 40) Patients with locoregionally recurrent ESCC after surgical resection will be enrolled into the postoperative locoregionally recurrent ESCC part (N = 10)